nodes	percent_of_prediction	percent_of_DWPC	metapath
Ziprasidone—CYP1A2—Pentoxifylline—systemic scleroderma	0.0401	0.255	CbGbCtD
Ziprasidone—CYP1A2—Leflunomide—systemic scleroderma	0.0383	0.243	CbGbCtD
Ziprasidone—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0318	0.202	CbGbCtD
Ziprasidone—HTR3A—myenteric nerve plexus—systemic scleroderma	0.0248	0.154	CbGeAlD
Ziprasidone—CYP2D6—Captopril—systemic scleroderma	0.0247	0.157	CbGbCtD
Ziprasidone—HTR7—myenteric nerve plexus—systemic scleroderma	0.016	0.0997	CbGeAlD
Ziprasidone—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0124	0.0788	CbGbCtD
Ziprasidone—HTR7—pulmonary artery—systemic scleroderma	0.0114	0.0706	CbGeAlD
Ziprasidone—HTR2A—myenteric nerve plexus—systemic scleroderma	0.01	0.0622	CbGeAlD
Ziprasidone—CYP3A4—Prednisone—systemic scleroderma	0.0099	0.063	CbGbCtD
Ziprasidone—HTR2A—pulmonary artery—systemic scleroderma	0.00709	0.044	CbGeAlD
Ziprasidone—HTR1B—artery—systemic scleroderma	0.00546	0.0339	CbGeAlD
Ziprasidone—HTR1D—artery—systemic scleroderma	0.00529	0.0328	CbGeAlD
Ziprasidone—HTR1B—blood vessel—systemic scleroderma	0.00425	0.0264	CbGeAlD
Ziprasidone—HTR7—artery—systemic scleroderma	0.00421	0.0262	CbGeAlD
Ziprasidone—HTR1D—blood vessel—systemic scleroderma	0.00412	0.0256	CbGeAlD
Ziprasidone—HTR7—endothelium—systemic scleroderma	0.00356	0.0221	CbGeAlD
Ziprasidone—HTR7—blood vessel—systemic scleroderma	0.00328	0.0204	CbGeAlD
Ziprasidone—CHRM5—skin of body—systemic scleroderma	0.00285	0.0177	CbGeAlD
Ziprasidone—H1F0—connective tissue—systemic scleroderma	0.00273	0.0169	CbGeAlD
Ziprasidone—HTR2A—artery—systemic scleroderma	0.00263	0.0163	CbGeAlD
Ziprasidone—H1F0—smooth muscle tissue—systemic scleroderma	0.00249	0.0155	CbGeAlD
Ziprasidone—H1F0—skin of body—systemic scleroderma	0.00246	0.0153	CbGeAlD
Ziprasidone—HTR2A—endothelium—systemic scleroderma	0.00222	0.0138	CbGeAlD
Ziprasidone—HTR1D—connective tissue—systemic scleroderma	0.00211	0.0131	CbGeAlD
Ziprasidone—HTR2A—blood vessel—systemic scleroderma	0.00205	0.0127	CbGeAlD
Ziprasidone—H1F0—digestive system—systemic scleroderma	0.00197	0.0122	CbGeAlD
Ziprasidone—HTR3A—digestive system—systemic scleroderma	0.00188	0.0117	CbGeAlD
Ziprasidone—H1F0—tendon—systemic scleroderma	0.00187	0.0116	CbGeAlD
Ziprasidone—HTR7—connective tissue—systemic scleroderma	0.00168	0.0104	CbGeAlD
Ziprasidone—H1F0—lung—systemic scleroderma	0.00164	0.0102	CbGeAlD
Ziprasidone—CHRM3—smooth muscle tissue—systemic scleroderma	0.00162	0.01	CbGeAlD
Ziprasidone—HTR3A—lung—systemic scleroderma	0.00157	0.00974	CbGeAlD
Ziprasidone—HTR7—smooth muscle tissue—systemic scleroderma	0.00154	0.00956	CbGeAlD
Ziprasidone—SLC6A4—digestive system—systemic scleroderma	0.00143	0.00889	CbGeAlD
Ziprasidone—CHRM3—digestive system—systemic scleroderma	0.00128	0.00793	CbGeAlD
Ziprasidone—HRH1—connective tissue—systemic scleroderma	0.00126	0.0078	CbGeAlD
Ziprasidone—ADRA2A—connective tissue—systemic scleroderma	0.00123	0.00766	CbGeAlD
Ziprasidone—HTR7—digestive system—systemic scleroderma	0.00122	0.00755	CbGeAlD
Ziprasidone—SLC6A4—lung—systemic scleroderma	0.0012	0.00743	CbGeAlD
Ziprasidone—CHRM1—lung—systemic scleroderma	0.00119	0.0074	CbGeAlD
Ziprasidone—HTR7—tendon—systemic scleroderma	0.00116	0.00718	CbGeAlD
Ziprasidone—HRH1—smooth muscle tissue—systemic scleroderma	0.00115	0.00714	CbGeAlD
Ziprasidone—ADRA2C—tendon—systemic scleroderma	0.00106	0.0066	CbGeAlD
Ziprasidone—HTR2A—connective tissue—systemic scleroderma	0.00105	0.00652	CbGeAlD
Ziprasidone—HTR7—lung—systemic scleroderma	0.00101	0.0063	CbGeAlD
Ziprasidone—CYP1A2—digestive system—systemic scleroderma	0.000969	0.00602	CbGeAlD
Ziprasidone—HTR2A—smooth muscle tissue—systemic scleroderma	0.00096	0.00596	CbGeAlD
Ziprasidone—DRD2—lung—systemic scleroderma	0.00096	0.00596	CbGeAlD
Ziprasidone—CYP3A5—digestive system—systemic scleroderma	0.000935	0.00581	CbGeAlD
Ziprasidone—ADRA2C—lung—systemic scleroderma	0.000933	0.00579	CbGeAlD
Ziprasidone—HRH1—digestive system—systemic scleroderma	0.000907	0.00564	CbGeAlD
Ziprasidone—HRH1—tendon—systemic scleroderma	0.000863	0.00536	CbGeAlD
Ziprasidone—ADRA2A—tendon—systemic scleroderma	0.000848	0.00527	CbGeAlD
Ziprasidone—CYP1A2—lung—systemic scleroderma	0.000809	0.00503	CbGeAlD
Ziprasidone—CYP3A5—lung—systemic scleroderma	0.000781	0.00485	CbGeAlD
Ziprasidone—HTR2A—digestive system—systemic scleroderma	0.000758	0.00471	CbGeAlD
Ziprasidone—HRH1—lung—systemic scleroderma	0.000758	0.00471	CbGeAlD
Ziprasidone—ADRA2A—lung—systemic scleroderma	0.000744	0.00462	CbGeAlD
Ziprasidone—HTR2A—tendon—systemic scleroderma	0.000721	0.00448	CbGeAlD
Ziprasidone—CYP3A4—digestive system—systemic scleroderma	0.000702	0.00436	CbGeAlD
Ziprasidone—CYP2D6—digestive system—systemic scleroderma	0.00069	0.00429	CbGeAlD
Ziprasidone—HTR2A—lung—systemic scleroderma	0.000633	0.00393	CbGeAlD
Ziprasidone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000307	0.000451	CcSEcCtD
Ziprasidone—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000307	0.000451	CcSEcCtD
Ziprasidone—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000307	0.00045	CcSEcCtD
Ziprasidone—Erectile dysfunction—Prednisone—systemic scleroderma	0.000306	0.000449	CcSEcCtD
Ziprasidone—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.000306	0.000449	CcSEcCtD
Ziprasidone—Feeling abnormal—Leflunomide—systemic scleroderma	0.000306	0.000448	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000305	0.000448	CcSEcCtD
Ziprasidone—Fatigue—Mycophenolic acid—systemic scleroderma	0.000305	0.000447	CcSEcCtD
Ziprasidone—Nausea—Mometasone—systemic scleroderma	0.000304	0.000446	CcSEcCtD
Ziprasidone—Anorexia—Lisinopril—systemic scleroderma	0.000304	0.000445	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000303	0.000445	CcSEcCtD
Ziprasidone—Weight increased—Prednisone—systemic scleroderma	0.000303	0.000444	CcSEcCtD
Ziprasidone—Ataxia—Methotrexate—systemic scleroderma	0.000302	0.000444	CcSEcCtD
Ziprasidone—Constipation—Mycophenolic acid—systemic scleroderma	0.000302	0.000444	CcSEcCtD
Ziprasidone—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000302	0.000443	CcSEcCtD
Ziprasidone—Weight decreased—Prednisone—systemic scleroderma	0.000301	0.000441	CcSEcCtD
Ziprasidone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000301	0.000441	CcSEcCtD
Ziprasidone—Hyperglycaemia—Prednisone—systemic scleroderma	0.0003	0.00044	CcSEcCtD
Ziprasidone—Cough—Mycophenolate mofetil—systemic scleroderma	0.000298	0.000438	CcSEcCtD
Ziprasidone—Hypotension—Lisinopril—systemic scleroderma	0.000298	0.000437	CcSEcCtD
Ziprasidone—Dizziness—Captopril—systemic scleroderma	0.000297	0.000436	CcSEcCtD
Ziprasidone—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000297	0.000436	CcSEcCtD
Ziprasidone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000295	0.000433	CcSEcCtD
Ziprasidone—Urticaria—Leflunomide—systemic scleroderma	0.000295	0.000432	CcSEcCtD
Ziprasidone—Abdominal pain—Leflunomide—systemic scleroderma	0.000293	0.00043	CcSEcCtD
Ziprasidone—Body temperature increased—Leflunomide—systemic scleroderma	0.000293	0.00043	CcSEcCtD
Ziprasidone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000291	0.000427	CcSEcCtD
Ziprasidone—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000291	0.000427	CcSEcCtD
Ziprasidone—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000291	0.000427	CcSEcCtD
Ziprasidone—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000291	0.000427	CcSEcCtD
Ziprasidone—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000291	0.000426	CcSEcCtD
Ziprasidone—Breast disorder—Methotrexate—systemic scleroderma	0.000291	0.000426	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00029	0.000426	CcSEcCtD
Ziprasidone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000426	CcSEcCtD
Ziprasidone—Hypersensitivity—Azathioprine—systemic scleroderma	0.000289	0.000424	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000289	0.000424	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000289	0.000424	CcSEcCtD
Ziprasidone—Insomnia—Lisinopril—systemic scleroderma	0.000288	0.000423	CcSEcCtD
Ziprasidone—Paraesthesia—Lisinopril—systemic scleroderma	0.000286	0.00042	CcSEcCtD
Ziprasidone—Vomiting—Captopril—systemic scleroderma	0.000286	0.000419	CcSEcCtD
Ziprasidone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000285	0.000418	CcSEcCtD
Ziprasidone—Dyspnoea—Lisinopril—systemic scleroderma	0.000284	0.000417	CcSEcCtD
Ziprasidone—Rash—Captopril—systemic scleroderma	0.000284	0.000416	CcSEcCtD
Ziprasidone—Dermatitis—Captopril—systemic scleroderma	0.000283	0.000416	CcSEcCtD
Ziprasidone—Somnolence—Lisinopril—systemic scleroderma	0.000283	0.000415	CcSEcCtD
Ziprasidone—Headache—Captopril—systemic scleroderma	0.000282	0.000413	CcSEcCtD
Ziprasidone—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000281	0.000413	CcSEcCtD
Ziprasidone—Dyspepsia—Lisinopril—systemic scleroderma	0.00028	0.000411	CcSEcCtD
Ziprasidone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00028	0.00041	CcSEcCtD
Ziprasidone—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00028	0.00041	CcSEcCtD
Ziprasidone—Infection—Mycophenolate mofetil—systemic scleroderma	0.000277	0.000407	CcSEcCtD
Ziprasidone—Decreased appetite—Lisinopril—systemic scleroderma	0.000277	0.000406	CcSEcCtD
Ziprasidone—Eosinophilia—Methotrexate—systemic scleroderma	0.000275	0.000404	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000275	0.000403	CcSEcCtD
Ziprasidone—Fatigue—Lisinopril—systemic scleroderma	0.000275	0.000403	CcSEcCtD
Ziprasidone—Shock—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000403	CcSEcCtD
Ziprasidone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000274	0.000401	CcSEcCtD
Ziprasidone—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000273	0.000401	CcSEcCtD
Ziprasidone—Hypersensitivity—Leflunomide—systemic scleroderma	0.000273	0.000401	CcSEcCtD
Ziprasidone—Constipation—Lisinopril—systemic scleroderma	0.000272	0.0004	CcSEcCtD
Ziprasidone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000272	0.000399	CcSEcCtD
Ziprasidone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000271	0.000398	CcSEcCtD
Ziprasidone—Bradycardia—Prednisone—systemic scleroderma	0.000271	0.000398	CcSEcCtD
Ziprasidone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00027	0.000396	CcSEcCtD
Ziprasidone—Diarrhoea—Azathioprine—systemic scleroderma	0.000269	0.000394	CcSEcCtD
Ziprasidone—Haemoglobin—Prednisone—systemic scleroderma	0.000268	0.000393	CcSEcCtD
Ziprasidone—Nausea—Captopril—systemic scleroderma	0.000267	0.000392	CcSEcCtD
Ziprasidone—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000267	0.000391	CcSEcCtD
Ziprasidone—Haemorrhage—Prednisone—systemic scleroderma	0.000266	0.000391	CcSEcCtD
Ziprasidone—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000266	0.00039	CcSEcCtD
Ziprasidone—Asthenia—Leflunomide—systemic scleroderma	0.000266	0.00039	CcSEcCtD
Ziprasidone—Feeling abnormal—Lisinopril—systemic scleroderma	0.000263	0.000385	CcSEcCtD
Ziprasidone—Connective tissue disorder—Prednisone—systemic scleroderma	0.000262	0.000384	CcSEcCtD
Ziprasidone—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000261	0.000382	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00026	0.000382	CcSEcCtD
Ziprasidone—Dysuria—Methotrexate—systemic scleroderma	0.00026	0.000381	CcSEcCtD
Ziprasidone—Dizziness—Azathioprine—systemic scleroderma	0.00026	0.000381	CcSEcCtD
Ziprasidone—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000258	0.000379	CcSEcCtD
Ziprasidone—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000256	0.000376	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000254	0.000373	CcSEcCtD
Ziprasidone—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.000254	0.000372	CcSEcCtD
Ziprasidone—Asthenia—Mycophenolic acid—systemic scleroderma	0.000254	0.000372	CcSEcCtD
Ziprasidone—Diarrhoea—Leflunomide—systemic scleroderma	0.000254	0.000372	CcSEcCtD
Ziprasidone—Urticaria—Lisinopril—systemic scleroderma	0.000253	0.000371	CcSEcCtD
Ziprasidone—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000252	0.00037	CcSEcCtD
Ziprasidone—Body temperature increased—Lisinopril—systemic scleroderma	0.000252	0.000369	CcSEcCtD
Ziprasidone—Abdominal pain—Lisinopril—systemic scleroderma	0.000252	0.000369	CcSEcCtD
Ziprasidone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000251	0.000368	CcSEcCtD
Ziprasidone—Vomiting—Azathioprine—systemic scleroderma	0.00025	0.000366	CcSEcCtD
Ziprasidone—Pneumonia—Methotrexate—systemic scleroderma	0.000249	0.000366	CcSEcCtD
Ziprasidone—Eye disorder—Prednisone—systemic scleroderma	0.000249	0.000365	CcSEcCtD
Ziprasidone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000249	0.000365	CcSEcCtD
Ziprasidone—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000248	0.000364	CcSEcCtD
Ziprasidone—Infestation—Methotrexate—systemic scleroderma	0.000248	0.000364	CcSEcCtD
Ziprasidone—Infestation NOS—Methotrexate—systemic scleroderma	0.000248	0.000364	CcSEcCtD
Ziprasidone—Rash—Azathioprine—systemic scleroderma	0.000248	0.000363	CcSEcCtD
Ziprasidone—Dermatitis—Azathioprine—systemic scleroderma	0.000247	0.000363	CcSEcCtD
Ziprasidone—Headache—Azathioprine—systemic scleroderma	0.000246	0.000361	CcSEcCtD
Ziprasidone—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000246	0.00036	CcSEcCtD
Ziprasidone—Dizziness—Leflunomide—systemic scleroderma	0.000245	0.00036	CcSEcCtD
Ziprasidone—Renal failure—Methotrexate—systemic scleroderma	0.000244	0.000357	CcSEcCtD
Ziprasidone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000243	0.000356	CcSEcCtD
Ziprasidone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000242	0.000355	CcSEcCtD
Ziprasidone—Angiopathy—Prednisone—systemic scleroderma	0.000242	0.000354	CcSEcCtD
Ziprasidone—Conjunctivitis—Methotrexate—systemic scleroderma	0.000241	0.000353	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000353	CcSEcCtD
Ziprasidone—Immune system disorder—Prednisone—systemic scleroderma	0.000241	0.000353	CcSEcCtD
Ziprasidone—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000239	0.00035	CcSEcCtD
Ziprasidone—Arrhythmia—Prednisone—systemic scleroderma	0.000238	0.000349	CcSEcCtD
Ziprasidone—Sweating—Methotrexate—systemic scleroderma	0.000238	0.000349	CcSEcCtD
Ziprasidone—Haematuria—Methotrexate—systemic scleroderma	0.000236	0.000347	CcSEcCtD
Ziprasidone—Vomiting—Leflunomide—systemic scleroderma	0.000236	0.000346	CcSEcCtD
Ziprasidone—Alopecia—Prednisone—systemic scleroderma	0.000235	0.000345	CcSEcCtD
Ziprasidone—Hypersensitivity—Lisinopril—systemic scleroderma	0.000235	0.000344	CcSEcCtD
Ziprasidone—Dizziness—Mycophenolic acid—systemic scleroderma	0.000234	0.000343	CcSEcCtD
Ziprasidone—Epistaxis—Methotrexate—systemic scleroderma	0.000234	0.000343	CcSEcCtD
Ziprasidone—Rash—Leflunomide—systemic scleroderma	0.000234	0.000343	CcSEcCtD
Ziprasidone—Dermatitis—Leflunomide—systemic scleroderma	0.000234	0.000342	CcSEcCtD
Ziprasidone—Mental disorder—Prednisone—systemic scleroderma	0.000233	0.000342	CcSEcCtD
Ziprasidone—Nausea—Azathioprine—systemic scleroderma	0.000233	0.000342	CcSEcCtD
Ziprasidone—Headache—Leflunomide—systemic scleroderma	0.000232	0.000341	CcSEcCtD
Ziprasidone—Erythema—Prednisone—systemic scleroderma	0.000232	0.00034	CcSEcCtD
Ziprasidone—Malnutrition—Prednisone—systemic scleroderma	0.000232	0.00034	CcSEcCtD
Ziprasidone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00023	0.000337	CcSEcCtD
Ziprasidone—Asthenia—Lisinopril—systemic scleroderma	0.000229	0.000335	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000228	0.000335	CcSEcCtD
Ziprasidone—Vomiting—Mycophenolic acid—systemic scleroderma	0.000225	0.00033	CcSEcCtD
Ziprasidone—Haemoglobin—Methotrexate—systemic scleroderma	0.000224	0.000328	CcSEcCtD
Ziprasidone—Rash—Mycophenolic acid—systemic scleroderma	0.000223	0.000327	CcSEcCtD
Ziprasidone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000223	0.000327	CcSEcCtD
Ziprasidone—Haemorrhage—Methotrexate—systemic scleroderma	0.000223	0.000326	CcSEcCtD
Ziprasidone—Hepatitis—Methotrexate—systemic scleroderma	0.000223	0.000326	CcSEcCtD
Ziprasidone—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000222	0.000325	CcSEcCtD
Ziprasidone—Headache—Mycophenolic acid—systemic scleroderma	0.000222	0.000325	CcSEcCtD
Ziprasidone—Pharyngitis—Methotrexate—systemic scleroderma	0.000221	0.000324	CcSEcCtD
Ziprasidone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000324	CcSEcCtD
Ziprasidone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000324	CcSEcCtD
Ziprasidone—Nausea—Leflunomide—systemic scleroderma	0.00022	0.000323	CcSEcCtD
Ziprasidone—Urinary tract disorder—Methotrexate—systemic scleroderma	0.00022	0.000322	CcSEcCtD
Ziprasidone—Vision blurred—Prednisone—systemic scleroderma	0.000218	0.00032	CcSEcCtD
Ziprasidone—Urethral disorder—Methotrexate—systemic scleroderma	0.000218	0.00032	CcSEcCtD
Ziprasidone—Diarrhoea—Lisinopril—systemic scleroderma	0.000218	0.00032	CcSEcCtD
Ziprasidone—Visual impairment—Methotrexate—systemic scleroderma	0.000214	0.000315	CcSEcCtD
Ziprasidone—Anaemia—Prednisone—systemic scleroderma	0.000214	0.000314	CcSEcCtD
Ziprasidone—Agitation—Prednisone—systemic scleroderma	0.000213	0.000312	CcSEcCtD
Ziprasidone—Angioedema—Prednisone—systemic scleroderma	0.000212	0.000311	CcSEcCtD
Ziprasidone—Dizziness—Lisinopril—systemic scleroderma	0.000211	0.000309	CcSEcCtD
Ziprasidone—Nausea—Mycophenolic acid—systemic scleroderma	0.00021	0.000308	CcSEcCtD
Ziprasidone—Vertigo—Prednisone—systemic scleroderma	0.000208	0.000305	CcSEcCtD
Ziprasidone—Eye disorder—Methotrexate—systemic scleroderma	0.000208	0.000305	CcSEcCtD
Ziprasidone—Syncope—Prednisone—systemic scleroderma	0.000208	0.000305	CcSEcCtD
Ziprasidone—Tinnitus—Methotrexate—systemic scleroderma	0.000208	0.000304	CcSEcCtD
Ziprasidone—Cardiac disorder—Methotrexate—systemic scleroderma	0.000207	0.000303	CcSEcCtD
Ziprasidone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000206	0.000302	CcSEcCtD
Ziprasidone—Loss of consciousness—Prednisone—systemic scleroderma	0.000204	0.000299	CcSEcCtD
Ziprasidone—Vomiting—Lisinopril—systemic scleroderma	0.000203	0.000297	CcSEcCtD
Ziprasidone—Angiopathy—Methotrexate—systemic scleroderma	0.000202	0.000296	CcSEcCtD
Ziprasidone—Immune system disorder—Methotrexate—systemic scleroderma	0.000201	0.000295	CcSEcCtD
Ziprasidone—Rash—Lisinopril—systemic scleroderma	0.000201	0.000295	CcSEcCtD
Ziprasidone—Dermatitis—Lisinopril—systemic scleroderma	0.000201	0.000294	CcSEcCtD
Ziprasidone—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000201	0.000294	CcSEcCtD
Ziprasidone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.0002	0.000294	CcSEcCtD
Ziprasidone—Hypertension—Prednisone—systemic scleroderma	0.0002	0.000294	CcSEcCtD
Ziprasidone—Chills—Methotrexate—systemic scleroderma	0.0002	0.000293	CcSEcCtD
Ziprasidone—Headache—Lisinopril—systemic scleroderma	0.0002	0.000293	CcSEcCtD
Ziprasidone—Myalgia—Prednisone—systemic scleroderma	0.000197	0.000289	CcSEcCtD
Ziprasidone—Arthralgia—Prednisone—systemic scleroderma	0.000197	0.000289	CcSEcCtD
Ziprasidone—Anxiety—Prednisone—systemic scleroderma	0.000197	0.000288	CcSEcCtD
Ziprasidone—Alopecia—Methotrexate—systemic scleroderma	0.000197	0.000288	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000196	0.000287	CcSEcCtD
Ziprasidone—Mental disorder—Methotrexate—systemic scleroderma	0.000195	0.000286	CcSEcCtD
Ziprasidone—Erythema—Methotrexate—systemic scleroderma	0.000194	0.000284	CcSEcCtD
Ziprasidone—Malnutrition—Methotrexate—systemic scleroderma	0.000194	0.000284	CcSEcCtD
Ziprasidone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000191	0.00028	CcSEcCtD
Ziprasidone—Nausea—Lisinopril—systemic scleroderma	0.000189	0.000277	CcSEcCtD
Ziprasidone—Infection—Prednisone—systemic scleroderma	0.000188	0.000276	CcSEcCtD
Ziprasidone—Back pain—Methotrexate—systemic scleroderma	0.000187	0.000275	CcSEcCtD
Ziprasidone—Shock—Prednisone—systemic scleroderma	0.000186	0.000273	CcSEcCtD
Ziprasidone—Nervous system disorder—Prednisone—systemic scleroderma	0.000186	0.000272	CcSEcCtD
Ziprasidone—Tachycardia—Prednisone—systemic scleroderma	0.000185	0.000271	CcSEcCtD
Ziprasidone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000271	CcSEcCtD
Ziprasidone—Skin disorder—Prednisone—systemic scleroderma	0.000184	0.00027	CcSEcCtD
Ziprasidone—Hyperhidrosis—Prednisone—systemic scleroderma	0.000183	0.000268	CcSEcCtD
Ziprasidone—Vision blurred—Methotrexate—systemic scleroderma	0.000183	0.000268	CcSEcCtD
Ziprasidone—Anorexia—Prednisone—systemic scleroderma	0.00018	0.000264	CcSEcCtD
Ziprasidone—Anaemia—Methotrexate—systemic scleroderma	0.000179	0.000263	CcSEcCtD
Ziprasidone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000177	0.00026	CcSEcCtD
Ziprasidone—Rash—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000258	CcSEcCtD
Ziprasidone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000176	0.000258	CcSEcCtD
Ziprasidone—Headache—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000256	CcSEcCtD
Ziprasidone—Vertigo—Methotrexate—systemic scleroderma	0.000174	0.000255	CcSEcCtD
Ziprasidone—Leukopenia—Methotrexate—systemic scleroderma	0.000173	0.000254	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000172	0.000253	CcSEcCtD
Ziprasidone—Insomnia—Prednisone—systemic scleroderma	0.000171	0.000251	CcSEcCtD
Ziprasidone—Paraesthesia—Prednisone—systemic scleroderma	0.00017	0.000249	CcSEcCtD
Ziprasidone—Cough—Methotrexate—systemic scleroderma	0.000169	0.000248	CcSEcCtD
Ziprasidone—Dyspepsia—Prednisone—systemic scleroderma	0.000167	0.000244	CcSEcCtD
Ziprasidone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000243	CcSEcCtD
Ziprasidone—Chest pain—Methotrexate—systemic scleroderma	0.000165	0.000242	CcSEcCtD
Ziprasidone—Arthralgia—Methotrexate—systemic scleroderma	0.000165	0.000242	CcSEcCtD
Ziprasidone—Myalgia—Methotrexate—systemic scleroderma	0.000165	0.000242	CcSEcCtD
Ziprasidone—Decreased appetite—Prednisone—systemic scleroderma	0.000164	0.000241	CcSEcCtD
Ziprasidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000164	0.00024	CcSEcCtD
Ziprasidone—Fatigue—Prednisone—systemic scleroderma	0.000163	0.000239	CcSEcCtD
Ziprasidone—Constipation—Prednisone—systemic scleroderma	0.000162	0.000237	CcSEcCtD
Ziprasidone—Confusional state—Methotrexate—systemic scleroderma	0.000159	0.000234	CcSEcCtD
Ziprasidone—Infection—Methotrexate—systemic scleroderma	0.000157	0.00023	CcSEcCtD
Ziprasidone—Feeling abnormal—Prednisone—systemic scleroderma	0.000156	0.000229	CcSEcCtD
Ziprasidone—Nervous system disorder—Methotrexate—systemic scleroderma	0.000155	0.000227	CcSEcCtD
Ziprasidone—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000155	0.000227	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000155	0.000227	CcSEcCtD
Ziprasidone—Skin disorder—Methotrexate—systemic scleroderma	0.000154	0.000225	CcSEcCtD
Ziprasidone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000153	0.000224	CcSEcCtD
Ziprasidone—Anorexia—Methotrexate—systemic scleroderma	0.000151	0.000221	CcSEcCtD
Ziprasidone—Urticaria—Prednisone—systemic scleroderma	0.00015	0.00022	CcSEcCtD
Ziprasidone—Abdominal pain—Prednisone—systemic scleroderma	0.00015	0.000219	CcSEcCtD
Ziprasidone—Body temperature increased—Prednisone—systemic scleroderma	0.00015	0.000219	CcSEcCtD
Ziprasidone—Hypotension—Methotrexate—systemic scleroderma	0.000148	0.000217	CcSEcCtD
Ziprasidone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000144	0.000211	CcSEcCtD
Ziprasidone—Insomnia—Methotrexate—systemic scleroderma	0.000143	0.00021	CcSEcCtD
Ziprasidone—Paraesthesia—Methotrexate—systemic scleroderma	0.000142	0.000208	CcSEcCtD
Ziprasidone—Dyspnoea—Methotrexate—systemic scleroderma	0.000141	0.000207	CcSEcCtD
Ziprasidone—Somnolence—Methotrexate—systemic scleroderma	0.000141	0.000206	CcSEcCtD
Ziprasidone—Hypersensitivity—Prednisone—systemic scleroderma	0.000139	0.000204	CcSEcCtD
Ziprasidone—Dyspepsia—Methotrexate—systemic scleroderma	0.000139	0.000204	CcSEcCtD
Ziprasidone—Decreased appetite—Methotrexate—systemic scleroderma	0.000137	0.000202	CcSEcCtD
Ziprasidone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000137	0.0002	CcSEcCtD
Ziprasidone—Fatigue—Methotrexate—systemic scleroderma	0.000136	0.0002	CcSEcCtD
Ziprasidone—Asthenia—Prednisone—systemic scleroderma	0.000136	0.000199	CcSEcCtD
Ziprasidone—Feeling abnormal—Methotrexate—systemic scleroderma	0.00013	0.000191	CcSEcCtD
Ziprasidone—Diarrhoea—Prednisone—systemic scleroderma	0.000129	0.00019	CcSEcCtD
Ziprasidone—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000129	0.00019	CcSEcCtD
Ziprasidone—Urticaria—Methotrexate—systemic scleroderma	0.000126	0.000184	CcSEcCtD
Ziprasidone—Dizziness—Prednisone—systemic scleroderma	0.000125	0.000183	CcSEcCtD
Ziprasidone—Abdominal pain—Methotrexate—systemic scleroderma	0.000125	0.000183	CcSEcCtD
Ziprasidone—Body temperature increased—Methotrexate—systemic scleroderma	0.000125	0.000183	CcSEcCtD
Ziprasidone—Vomiting—Prednisone—systemic scleroderma	0.00012	0.000176	CcSEcCtD
Ziprasidone—Rash—Prednisone—systemic scleroderma	0.000119	0.000175	CcSEcCtD
Ziprasidone—Dermatitis—Prednisone—systemic scleroderma	0.000119	0.000175	CcSEcCtD
Ziprasidone—Headache—Prednisone—systemic scleroderma	0.000119	0.000174	CcSEcCtD
Ziprasidone—Hypersensitivity—Methotrexate—systemic scleroderma	0.000116	0.000171	CcSEcCtD
Ziprasidone—Asthenia—Methotrexate—systemic scleroderma	0.000113	0.000166	CcSEcCtD
Ziprasidone—Nausea—Prednisone—systemic scleroderma	0.000112	0.000165	CcSEcCtD
Ziprasidone—Diarrhoea—Methotrexate—systemic scleroderma	0.000108	0.000159	CcSEcCtD
Ziprasidone—Dizziness—Methotrexate—systemic scleroderma	0.000105	0.000153	CcSEcCtD
Ziprasidone—Vomiting—Methotrexate—systemic scleroderma	0.000101	0.000147	CcSEcCtD
Ziprasidone—Rash—Methotrexate—systemic scleroderma	9.97e-05	0.000146	CcSEcCtD
Ziprasidone—Dermatitis—Methotrexate—systemic scleroderma	9.96e-05	0.000146	CcSEcCtD
Ziprasidone—Headache—Methotrexate—systemic scleroderma	9.91e-05	0.000145	CcSEcCtD
Ziprasidone—Nausea—Methotrexate—systemic scleroderma	9.39e-05	0.000138	CcSEcCtD
